ANAB:NGS-AnaptysBio Inc. (USD)

COMMON STOCK | Biotechnology | Nasdaq Global Select

Last Closing

USD 18.95

Change

0.00 (0.00)%

Market Cap

USD 0.57B

Volume

0.81M

Analyst Target

USD 18.14
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AnaptysBio Inc is a biotechnology company. The Company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing ANAB

BBC Virtus LifeSci Biotech Cl.. 1.21 % 0.79 %

N/A

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.13% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.13% 94% A 95% A
Trailing 12 Months  
Capital Gain -15.85% 73% C 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.85% 73% C 41% F
Trailing 5 Years  
Capital Gain 34.11% 78% C+ 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.11% 78% C+ 48% F
Average Annual (5 Year Horizon)  
Capital Gain 7.90% 60% D- 60% D-
Dividend Return 7.90% 60% D- 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.38% 78% C+ 52% F
Risk Adjusted Return 22.32% 81% B- 57% F
Market Capitalization 0.57B 73% C 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.